RATIONAL THERAPY OF PSYCHOVEGETATIVE DISORDERS IN GENERAL MEDICAL PRACTICE


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Peculiarities of anxiety disorders (AD), taking a leading place among illnesses, accompanying by vegetative nervous system disfunction, are considered. AD include generalized anxiety, panic, obscessive-compulsive and phobic disorders, and also posttraumatic stress disorder. Taking into account obligate coexistence of psychic symtomes of anxiety and its somatoneurological manifestations the term «psychovegetative disturbances» describing abovementioned symptom complex was adopted. Drugs of choice for AD treatment are selective serotonin reuptake inhibitors. Nevertheless, they have some disadvantages (slow getting the effect, side effects including sexual dysfunction). Benzodiazepines give fast antianxiety effect, but risk-benefit profile of these meducaments does not let to prescribe them for a long time. The question of possibilities of use of nonbenzodiazepine antianxiety remedies which are exeeding benzodiazepines for their safety for AD therapy is under detailed discussion.

全文:

受限制的访问

作者简介

Yuliya Azimova

University Headache Clinic

Email: azimova.j@mail.ru
PhD, neurologist 121467, Moscow, 2/1 Molodogvardeyskaya St

参考

  1. Арушанян Э.Б., Мастягина О.А., Мастягин С.С., Попова А.П. Некоторые особенности влияния тофизопама и экстракта валерианы на память и тревожность у человека. Клин. экспер. фармакол. 2004;67(6):23-5.
  2. Bandelow B., Sher L., Bunevicius R., Hollander E., Kasper S., Zohar J., Möller H.J. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsivedisorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 2012;16(2):77-84.
  3. Bernasconi F., Kometer M., Pokorny T., Seifritz E., Vollenweider F.X. The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. Eur. Neuropsychopharmacol. 2015;25(4):474-82.
  4. Brawman-Mintzer O., Lydiard R.B., Crawford M.M., Emmanuel N., Payeur R., Johnson M., Knapp R.G., Ballenger J.C. Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders. Am. J. Psychiatry. 1994;151(6):930-2.
  5. Chamberlain S.R., Müller U., Deakin J.B., Corlett P.R., Dowson J., Cardinal R.N., Aitken M.R., Robbins T.W., Sahakian B.J. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J. Psychopharmacol. 2007;21(2):210-5.
  6. Cho S., Chu M.K. Risk Factors of Chronic Daily Headache or Chronic Migraine. Curr. Pain Headache Rep. 2015;19:465.
  7. Cottraux J., Note I.D., Cungi C., Légeron P., Heim F., Chneiweiss L., Bernard G., Bouvard M. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br. J. Psychiatry. 1995;167(5):635-41.
  8. Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl). 1991;105(3):428-32.
  9. Goldberg H.L., Finnerty R.J. Comparative efficacy of tofisopam and placebo. Am. J. Psychiatry. 1979;136(2):196-9.
  10. Kessler R.C., Ruscio A., Shear K., et al. Epidemiology of anxiety disorders. M.B. Stein and T. Steckler (eds.). Behavioral neurobiology of anxiety and its treatment, current topics in behavioral neurosciences 2. 2009.
  11. Koudas V., Nikolaou A., Hourdaki E., Giakoumaki S.G., Roussos P., Bitsios P. Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers. Psychopharmacology (Berl). 2009;205(1):1-9.
  12. Landén M., Eriksson E., Agren H., Fahlén T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 1999;19(3):268-71.
  13. Lee S.T., Park J.H., Kim M. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache. 2005;45(8):1004-11.
  14. Mitsikostas D.D., Gatzonis S., Thomas A., Ilias A. Buspirone vs amitriptyline in the treatment of chronic tension-type headache. Acta Neurol. Scand. 1997;96(4):247-51.
  15. Mokhber N., Azarpazhooh M.R., Khajehdaluee M., Velayati A., Hopwood M. Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder. Psychiatry Clin. Neurosci. 2010;64(2):128-33.
  16. Nazari H., Yari F., Jariani M., Marzban A., Birgandy M. Premenstrual syndrome: a single-blind study of treatment with buspirone versus fluoxetine. Arch. Gynecol. Obstet. 2013;287(3):469-72.
  17. Romera I., Fernández-Pérez S., Montejo A.L., Caballero F., Caballero L., Arbesu J.A., Delgado-Cohen H., Desaiah D., Polavieja P., Gilaberte I. Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. J. Affect Disord. 2010;127(1-3):160-8.
  18. Rush A.J., Batey S.R., Donahue R.M., Ascher J.A., Carmody T.J., Metz A. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J. Affect Disord. 2001;64(1):81-7.
  19. Rynn M., García-España F., Greenblatt D.J., Mandos L.A., Schweizer E., Rickels K. Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. J. Clin. Psychopharmacol. 2003;23(5):505-8.
  20. Tack J., Janssen P., Masaoka T., Farré R., Van Oudenhove L. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin. Gastroenterol. Hepatol. 2012;10(11):1239-45.
  21. WHO. The ICD-10 Classification of Mental and Behavioural Disorder: Clinical descriptions and diagnostic guidelines. F10-F19.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2017
##common.cookie##